Morgan Stanley Downgrades ResMed (RMD) to Underweight
More News related to RMD
- Notable Analyst Rating Changes 11/19: PSUN, LPX, SJM, SAFM Upgraded; SUN, SOL, GLW, CTRP Downgraded
- Jefferies & Co Initiates Coverage on ResMed (RMD)
- ResMed (RMD) Misses Q3 View By 2c
- ResMed Inc Announces Record Financial Results for the Quarter Ended September 30, 2008
- Trading Radar for 11/06: Disney (DIS), Anheuser-Busch (BUD), NVIDIA (NVDA), Nasdaq (NDAQ), Toyota (TM), Priceline.com (PCLN) Reports; Initial Jobless Claims, Preliminary Productivity for Q3 Due
More News related to Downgrades
- Citi Maintains a 'Hold' Rating on Intuit (INTU), Lowers Price Target
- Piper Jaffray Reiterates a 'Buy' Rating on Broadcom (BRCM), Lowers Price Target and Estimates
- Analyst Defends Google (GOOG), Says Search Ads Will Hold Up Well
- Susquehanna Maintains a 'Positive' Rating on Tween Brands (TWB), Lowers FY09 Estimates
- Citi Reiterates a 'Hold' on BJ's Wholesale (BJ), Turnaround Success Trumps Tough Environment
Morgan Stanley downgrades ResMed (NYSE: RMD) from Equalweight to Underweight.
ResMed, Inc. engages in the design, manufacture, and marketing of equipment for the diagnosis and treatment of -disordered breathing, including obstructive sleep apnea, and other respiratory disorders that occur during sleep.
Related Categories
DowngradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
